Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA budget

This article was originally published in The Tan Sheet

Executive Summary

The final fiscal year 2007 enacted budget for FDA is $1.57 bil., according to a recent FDA announcement. The amount represents an increase of $84 mil. over the full-year continuing resolution reported for FY 2007 in the president's FY 2008 budget request. The new funding level includes increases to food defense, which was awarded an additional $14 mil., and drug safety, which was awarded an additional $6 mil. The Office of Women's Health was awarded $4 mil., which represents an increase over the FY 2006 amount of $3.96 mil. Rep. Rosa DeLauro, D-Conn., recently introduced legislation to protect OWH funding (1"The Tan Sheet" March 5, 2007, p. 19)...

You may also be interested in...



Bill Would Require Plan B Workshop, Elevate FDA’s Office Of Women’s Health

A House Judiciary subcommittee chair will reintroduce a bill that would require FDA to conduct a scientific workshop to examine data on the use of Barr's Plan B emergency contraceptive in women under age 18

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS100336

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel